multi-gene HIV alphavaccine product / AlphaVax - LARVOL DELTA

Mosaic HIV-1 vaccination induces anti-viral CD8 T cell functionality in the phase 1/2a clinical trial APPROACH. (PubMed, J Virol) - "Here, we tested ex vivo viral inhibitory activity of T cell responses induced by a multivalent HIV vaccine based on the replication-incompetent recombinant adenovirus serotype 26 vector with a mosaic immunogen strategy (Ad26.Mos.HIV), designed for broad immune coverage of diverse HIV-1 strains...T cell responses induced by the adenovirus serotype 26 (Ad26) mosaic vaccine regimen were assessed previously by IFN-γ ELISpot and flow cytometric assays, yet these assays only measure cytokine production but not the capacity of CD8+ T cells to inhibit replication of HIV-1. In this study, we demonstrate direct anti-viral function of the clinical Ad26 mosaic vaccine regimen through ex vivo inhibition of replication of diverse clades of HIV-1 isolates in the participant's own CD4+ T cells."

Journal • P1/2 data • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • IFNG

[VIRTUAL] Multivalent antigen presentation increases the antibody binding breadth and neutralizing potency upon the immunization with a self-assembling HIV env vaccine (HIVR4P 2021) - "BACKGROUND: Although previous studies have demonstrated that antigen valency is important to diversify the B cell repertoire, the ability of multivalent HIV vaccines to increase the breadth of vaccine-elicited antibodies and to promote neutralization remain unclear... We demonstrated that increasing the antigen valency by Q11 conjugation enhanced the humoral response in two distinct animal models, showing the potential of such nanomaterial in vaccine delivery. As a more clinically relevant model is required to further assess this platform, we plan to conjugate SOSIP trimer to Q11 and assess its immunogenicity in non-human primates."

Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. (PubMed, Lancet HIV) - P1 | "Co-administration of gp120 Env protein components with DNA or NYVAC vectors during priming led to early and potent induction of Env V1/V2 IgG binding antibody responses. This immunisation approach should be considered for induction of preventive antibodies in future HIV vaccine efficacy trials."

Clinical • Journal • P1 data • Allergy • Gene Therapies • Immunology • Infectious Disease • Mood Disorders